Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 3, 2012, Pages 315-321

  Shin, Jaeseung ^a   Choi, Sungeun ^a   Lee, Ji E ^a   Lee, Hye Sun ^a   Sohn, Young H ^a   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHOLINERGIC PATHWAYS HYPERINTENSITIES SCALE; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RATING SCALE; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; WHITE MATTER HYPERINTENSITY;

EID: 84862785905     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-300872     Document Type: Article

References (35)

1. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:566-71.
2. de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005;62:1265-9. (Pubitemid 41168354)
3. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004;19:1043-9. (Pubitemid 39302836)
4. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-92. (Pubitemid 36314364)
5. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-7. (Pubitemid 47325034)
6. Janvin CC, Larsen JP, Aarsland D, et al. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-9. (Pubitemid 44613283)
7. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-22.
8. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273-8.
9. Choi SH, Jung TM, Lee JE, et al. Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status. Neurobiol Aging. (In press). Published Online First: 8 January 2011. doi:10.1016/j.neurobiolaging. 2010.11.015.
10. De Groot JC, De Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002;52:335-41. (Pubitemid 35001500)
11. Garde E, Mortensen EL, Krabbe K, et al. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000;356:628-34. (Pubitemid 30627589)
12. Carmichael O, Schwarz C, Drucker D, et al. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370-8.
13. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004;63:246-53. (Pubitemid 38971122)
14. Bocti C, Swartz RH, Gao FQ, et al. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 2005;36:2126-31. (Pubitemid 41429232)
15. Beyer MK, Aarsland D, Greve OJ, et al. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006;21:223-9.
16. Lee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010;24:227-33.
17. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
18. Kang Y, Na DL. Seoul neuropsychological screening battery. Brain Research and Consulting Co, 2003.
19. Lee JE, Park HJ, Park B, et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010;81:320-6.
20. Kim H, Na DL. Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol 1999;21:127-33. (Pubitemid 29332001)
21. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
22. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707. (Pubitemid 47597592)
23. Yue NC, Arnold AM, Longstreth WT Jr, et al. Sulcal, ventricular, and white matter changes at MR imaging in the aging brain: data from the cardiovascular health study. Radiology 1997;202:33-9. (Pubitemid 27024105)
24. Rosner B. Fundamentals of biostatistics. 6th edn. Belmont, CA: Thomson-Brooks/Cole, 2006.
25. Behl P, Bocti C, Swartz RH, et al. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 2007;64:266-72.
26. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-9.
27. Marshall GA, Shchelchkov E, Kaufer DI, et al. White matter hyperintensities and cortical acetylcholinesterase activity in parkinsonian dementia. Acta Neurol Scand 2006;113:87-91.
28. Baxter MG, Chiba AA. Cognitive functions of the basal forebrain. Curr Opin Neurobiol 1999;9:178-83. (Pubitemid 29201789)
29. Niewiadomska G, Baksalerska-Pazera M, Riedel G. The septo-hippocampal system, learning and recovery of function. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:791-805.
30. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-7. (Pubitemid 43255898)
31. de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002;125:765-72. (Pubitemid 34279772)
32. Murray AD, Staff RT, Shenkin SD, et al. Brain white matter hyperintensities: relative importance of vascular risk factors in nondemented elderly people. Radiology 2005;237:251-7. (Pubitemid 41346171)
33. Lee PH, Kim HS, Lee JE, et al. Comparison of endothelial progenitor cells in Parkinson's disease patients treated with levodopa and levodopa/COMT inhibitor. Plos One 2011;6:e21536.
34. Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, et al. Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts. Stroke 2008;39:2158-65.
35. Jickling G, Salam A, Mohammad A, et al. Circulating endothelial progenitor cells and age-related white matter changes. Stroke 2009;40:3191-6.